The stock jumped over 105% in premarket trading on February 10, 2026, from a previous close of $1.50 to around $3.18, following the public surfacing of a Schedule 13G SEC filing by Goldman Sachs. Filed on January 6, 2026, for a 6.8% stake (196,537 shares) held as of December 31, 2025, the passive investment disclosure gained traction late February 9 into premarket hours via financial news outlets and social media chatter. This amplified retail interest in the low-float biotech, driving high volume and momentum absent other immediate news.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.